Time to meaningful clinical response in reduction of itch in atopic dermatitis

Abstract

Introduction: Itch is a distressing atopic dermatitis (AD) symptom that impacts quality of life. With the emergence of multiple new agents for the treatment of AD, the ability and speed with which an agent reduces itch may factor in agent selection.

Objective: In this study, the primary objective was to quantify the rate at which agents for AD provide itch reduction using the peak itch numerical rating scale (NRS) data from phase II and III clinical trials.

Methods: A PubMed literature search was performed in February 2020 to find phase II and III randomized clinical trials for the treatment of AD published from 2014 to 2020. A TIMEACLIR-Itch value was calculated from NRS data to represent the time to meaningful itch reduction.

Results: We find a shorter TIme to achieving a MEAningful CLInical Response for itch reduction (TIMEACLIR-Itch) for small molecule inhibitors when compared to biologic agents. We also observe that nemolizumab achieves TIMEACLIR-Itch more quickly than IL-4 or IL-4/13 agents.

Conclusion: These findings support the role that IL-31 has in producing itch and the role Janus kinase inhibitors (JAKinibs) play in itch reduction. This comparison of TIMEACLIR-Itch for different treatments may help guide therapy and management for AD patients.

Keywords:

• Clinimetrics
• comparative efficacy
• skin

Acknowledgements

We thank Drs. Wenda Zick of Eli Lilly and Mary Severin of AbbVie for providing clinical trials data.

Disclosure statement

Alan Fleischer is a consultant for Dermavant, Incyte, Qurient, SCM Lifescience, and Syneos. He is an investigator for Galderma, Menlo and Trevi.